Profile of Immunoglobulin G N-Glycome in COVID-19 Patients: A Case-Control Study

Front Immunol. 2021 Sep 23:12:748566. doi: 10.3389/fimmu.2021.748566. eCollection 2021.

Abstract

Coronavirus disease 2019 (COVID-19) remains a major health challenge globally. Previous studies have suggested that changes in the glycosylation of IgG are closely associated with the severity of COVID-19. This study aimed to compare the profiles of IgG N-glycome between COVID-19 patients and healthy controls. A case-control study was conducted, in which 104 COVID-19 patients and 104 age- and sex-matched healthy individuals were recruited. Serum IgG N-glycome composition was analyzed by hydrophilic interaction liquid chromatography with the ultra-high-performance liquid chromatography (HILIC-UPLC) approach. COVID-19 patients have a decreased level of IgG fucosylation, which upregulates antibody-dependent cell cytotoxicity (ADCC) in acute immune responses. In severe cases, a low level of IgG sialylation contributes to the ADCC-regulated enhancement of inflammatory cytokines. The decreases in sialylation and galactosylation play a role in COVID-19 pathogenesis via the activation of the lectin-initiated alternative complement pathway. IgG N-glycosylation underlines the complex clinical phenotypes of SARS-CoV-2 infection.

Keywords: COVID-19; IgG; SARS-CoV-2; case-control study; glycosylation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibody-Dependent Cell Cytotoxicity
  • COVID-19 / metabolism*
  • Case-Control Studies
  • Chromatography, High Pressure Liquid
  • Complement Pathway, Mannose-Binding Lectin
  • Female
  • Glycosylation
  • Humans
  • Immunoglobulin G / metabolism*
  • Male
  • Middle Aged
  • Phenotype
  • SARS-CoV-2 / physiology*

Substances

  • Immunoglobulin G
  • glycosylated IgG